Teva Pharmaceutical Industries Ltd 

TEVA:NYSE

LastChange / % ChangeDividend YieldVolumeAvg Volume (10 day)
50.67 -0.78   -1.52%2.58%3,444,7955.9M
Market data is delayed by at least 20 minutes.
Summary chart showing the current equity's performance of over the past 1 days
  • Advanced Charts
  • Embed the above chart in your blog or website

    Customize, copy, and then paste the generated code into your website.

Previous close 4/23/2014

Latest News Headlines for Teva Pharmaceutical Industries Ltd

Appointments, Network Agreements, Earnings Results Schedules, and Legal Claims - Analyst Notes on Alexion, Humana, Eli Lilly, Teva and Cigna

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, April 23, 2014 /PRNewswire/ -- Today, Analysts Review released its analysts' notes regarding Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), Humana Inc. (NYSE: HUM), Eli Lilly & Co. (NYSE: LLY), Teva Pharmaceutical Industries Limited (NYSE: TEVA) and Cigna Corp (NYSE: CI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1465-100free.

(CNW) OncoGenex Announces Fast Track Designation Granted for Custirsen in Combination with Cabazitaxel/Prednisone as Second-line Chemotherapy in Phase 3 AFFINITY Trial of Men with Metastatic Castrate-Resistant Prostate Cancer

Third Phase 3 Trial of Custirsen to Receive FDA Fast Track Designation BOTHELL, Wash. and VANCOUVER, British Columbia, April 23, 2014 /CNW/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the investigation of custirsen when administered in combination with cabazitaxel/prednisone for the treatment of men with metastatic castrate-resistant prostate cancer (CRPC) following prior treatment with a docetaxel-containing regimen.

OncoGenex Announces Fast Track Designation Granted for Custirsen in Combination with Cabazitaxel/Prednisone as Second-line Chemotherapy in Phase 3 AFFINITY Trial of Men with Metastatic Castrate-Resistant Prostate Cancer

Third Phase 3 Trial of Custirsen to Receive FDA Fast Track Designation BOTHELL, Wash. and VANCOUVER, British Columbia, April 23, 2014 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the investigation of custirsen when administered in combination with cabazitaxel/prednisone for the treatment of men with metastatic castrate-resistant prostate cancer (CRPC) following prior treatment with a docetaxel-containing regimen.

View more recent headlines

Company Background

Teva Pharmaceutical Industries Ltd (Teva) is an Israel-based pharmaceutical and drug company. It develops, produces and markets generic drugs in all treatment categories. The Company has a pharmaceutical business, whose principal products include Copaxone and Azilect. Teva's active pharmaceutical ingredient (API) business provides vertical integration to Teva's own pharmaceutical production. The Company's global operations are conducted from North and Latin America to Europe and Asia. Teva operates a number of subsidiaries in such countries as Canada, Croatia, the Czech Republic, France, Germany, Hungary, Ireland, Israel, Japan, Poland, the Russian Federation, Spain, the Netherlands, the United Kingdom and the United States. In February 2014, the Company's subsidiary, Train Merger Sub, Inc, fully acquired NuPathe Inc.

http://www.tevapharm.com

Loading...
Bid/SizeAsk/Size
-- / ---- / --
Price OpenPrevious Close
51.2250.67
Day HighDay Low
51.7350.67
52wk High/Date52wk Low/Date
54.70 / 4/2/201436.26 / 11/5/2013
% off 52wk High% off 52wk Low
-7.37%39.74%
Beta (5 Yr)Market Capitalization
0.748.1B Large Cap
Shares OutstandingVolatility Avg
949.7M23.26
EPS(TTM)P/E Ratio
1.4933.9
Dividend AnnouncementDividend Yield
2/8/20142.58%
Ex-DateDate of Record
2/20/20142/24/2014
PayablePayable Date
0.3447 - QRTR3/10/2014

Last Trade as of 4/23/2014 4:03 PM ET

Peers Information HelpTEVA Teva Pharmaceutical Industries Ltd vs. Peers

Peers 
TEVA
Teva Pharmaceutical Industries Ltd
26.42%
Biogen Idec Inc
9.52%
TEVA
Teva Pharmaceutical Industries Ltd
2.58%
Biogen Idec Inc
--
TEVA
Teva Pharmaceutical Industries Ltd
-1.52%
Biogen Idec Inc
0.18%
Compare these stocks